以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 有网友爆料……为应对我国日益突出的肥胖挑战，国家卫生健康委员会等多部门联合推出了为期三年的"体重管理年"专项行动。现将该行动方 案的相关政策文件及数据支撑内容整理如下： ▍文件发布 发布时间：2024年6月 ▍行动目标 自2024年起，计划用约三年时间，全面打造体重管理支持环境，显著提升全民体重管理意识与能力，推动健康生活方式深入人心。 力求实现全民参与、人人受益的体重管理新格局，让部分人群的体重异常状况得到有效改善。 ▍具体数据与措施 1. 超重肥胖形势不容乐观 • 《2025世界肥胖地图》数据显示，2025年中国将有41%的成年人属于高BMI（身体质量指数）人群，9%的成年人将达到肥胖标准。 发布机构：国家卫生健康委员会联合教育部、体育总局、国家中医药局等16个相关部门 文件标题：《"体重管理年"活动实施方案》 ▍具体实施 • 《中国居民营养与慢性病状况报告（2020年）》指出，2018年我国18岁及以上居民超重率为34.3%，肥胖率为16.4%， ...

Core Viewpoint - The article emphasizes the launch of a three-year "Weight Management Year" initiative by the National Health Commission to promote healthy living and address the rising obesity rates in China [3][5]. Group 1: Background and Context - The initiative is part of the "Healthy China 2030" strategy, aiming to create a supportive environment for weight management nationwide [5]. - The prevalence of overweight and obesity among Chinese adults is alarming, with over half of the adult population classified as overweight (34.3%) or obese (16.4%) [11]. - The report predicts that by 2030, the obesity rate among adults in China could reach 65.3% [11]. Group 2: Health Risks Associated with Obesity - Obesity is linked to various chronic diseases, including hypertension, diabetes, cardiovascular diseases, and certain cancers [5][12]. - The World Health Organization identifies obesity as the fifth leading risk factor for global health [12]. - Medical expenses related to overweight and obesity in China are projected to reach 418 billion RMB by 2030, accounting for 21.5% of national healthcare costs [12]. Group 3: Guidelines for Weight Management - The article outlines the definition of overweight and obesity based on Body Mass Index (BMI) standards, with a BMI of 24-28 classified as overweight and 28 or above as obese [7]. - It stresses the importance of personal responsibility in managing weight and adopting a healthy lifestyle [5][23]. - Effective weight management should follow three principles: safety, effectiveness, and comprehensive prevention [22]. Group 4: Strategies for Weight Loss - The core principle of weight loss is to consume fewer calories and increase physical activity, creating a negative balance in fat storage [21]. - The article encourages immediate action to enhance health awareness and suggests that the use of GLP-1 medications could help reverse the obesity trend in the next decade [22].

Core Viewpoint - The recent study from Harvard University reveals that the effectiveness of low-carbohydrate diets (LCDs) for weight loss is highly dependent on food quality rather than merely reducing carbohydrate intake, challenging traditional beliefs about dieting [5][7][12]. Summary by Sections Low-Carbohydrate Diets and Weight Loss - Traditional views suggest that strict carbohydrate control leads to effective weight loss, but the new research indicates that not all low-carb diets are beneficial; the quality of food consumed is crucial [5][7]. - A large-scale study involving over 12,000 participants shows that diets high in animal protein and refined fats yield limited weight loss and may even cause weight rebound [5][8]. Food Quality vs. Quantity - The study emphasizes that the quality of macronutrients is more important than simply counting carbohydrates; diets rich in plant proteins, healthy fats, and whole grains are more effective for weight maintenance [7][8][12]. - Those who prefer red meat and processed foods within low-carb diets experienced greater weight gain compared to those on a standard diet, highlighting the importance of food choices [5][8]. Personalized Nutrition - The effectiveness of plant-based low-carb diets varies based on individual body mass index (BMI), with overweight individuals (BMI 25-30) benefiting the most from such diets [10][12]. - The research suggests that personalized dietary plans should consider individual metabolic conditions, as the same diet may not work for everyone [10][12]. Implications for Weight Management - The findings provide a new perspective on weight management, advocating for a focus on high-quality nutrients rather than just reducing carbohydrate intake [12]. - This research is expected to influence global dietary guidelines, promoting a shift towards more personalized and scientifically-backed nutritional strategies [12][13].

Core Viewpoint - JD Health is establishing a comprehensive and multi-layered service system in the weight loss sector, integrating medical resources, innovative drug introduction, health management services, AI technology, and a strong supply chain to provide a full-chain solution for scientific weight loss [1][5]. Group 1: Innovative Drug Introduction - JD Health collaborates with renowned domestic and international pharmaceutical companies to introduce innovative weight loss drugs, ensuring users have access to cutting-edge weight loss solutions [2]. - The recently launched drug, "Xin Er Mei" (Magsduet injection), is the world's first approved GCG/GLP-1 dual receptor agonist for weight loss, which improves both weight and metabolic indicators while effectively reducing visceral fat [2]. - The drug features a painless injection technology that enhances the user experience, allowing users to easily connect with offline medical institutions through the JD APP [2]. Group 2: Comprehensive Service System - JD Health has initiated the "Scientific Weight Management Ecological Co-construction Initiative" to build a full-chain service system encompassing prevention, diagnosis, and management [4]. - The JD Internet Hospital collaborates with top doctors to offer personalized weight loss plans, having served over 10,000 users with a satisfaction rate of 99% [4]. - The "Simai Companion Six-in-One Test" project provides convenient home testing services for users of GLP-1 drugs, ensuring safe and effective medication [4]. Group 3: AI and Technology Integration - JD Health leverages its self-developed "JD Medical Qianxun" model to create AI tools such as AI doctors, AI pharmacists, and AI nutritionists, providing 24/7 online consultation services [4]. - These AI tools generate personalized dietary and exercise recommendations based on users' health conditions and weight loss goals, while also monitoring progress and adjusting plans in real-time [4]. Group 4: Supply Chain and Market Position - JD Health demonstrates strong supply chain advantages and service capabilities in the weight loss sector, responding to the "Weight Management Year" policy and promoting the adoption of scientific weight loss concepts [5]. - The company aims to provide efficient, inclusive, and professional health management solutions for an increasing number of users needing weight loss support [5].

Core Viewpoint - The article emphasizes the growing recognition of obesity as a medical condition rather than a personal failing, highlighting the need for systemic intervention and support in managing weight and related health issues [3][4][7]. Group 1: Current State of Obesity in China - As of 2018, the overweight rate among adults in China was 34.3%, with an obesity rate of 16.4%, translating to approximately 182 million adults suffering from obesity [3]. - Public perception often misattributes obesity to personal lack of discipline, which complicates access to medical support for those affected [3][9]. Group 2: Policy and Medical Response - The National Health Commission and the National Administration of Traditional Chinese Medicine plan to establish weight management clinics in hospitals by June 2025, aiming for comprehensive coverage [4]. - The "Weight Management Year" initiative is part of a broader public health strategy to enhance awareness and skills related to weight management across the population [11][21]. Group 3: Changing Perceptions and Treatment Approaches - A significant portion of the public (84%) attributes obesity to personal self-control issues, while only about 60% recognize genetic and environmental factors as contributors [7]. - New medications, such as GLP-1 receptor agonists, are changing the treatment landscape for obesity, allowing for more effective management of weight and associated metabolic conditions [16][18]. Group 4: Integrated Weight Management Systems - The article discusses the establishment of integrated weight management systems in hospitals, which include a multidisciplinary approach involving doctors, nutritionists, and health managers [12][14]. - The "1+3+N" model implemented in hospitals aims to provide comprehensive care from screening to treatment and management, reflecting a shift towards a more collaborative healthcare approach [12][14]. Group 5: Community and Societal Engagement - The article highlights the importance of community involvement in weight management, advocating for initiatives that promote healthy lifestyles at the family, community, and workplace levels [14][21]. - Public support for integrating obesity prevention into national health strategies is strong, with many favoring practical interventions like community fitness facilities [19][22].

Core Insights - The article highlights the launch of a new weight loss drug, Xinermai (generic name: Masitide Injection), developed by Innovent Biologics, which is the world's first GCG/GLP-1 dual receptor agonist approved for weight management in adults with obesity or overweight [1][3]. Industry Overview - Obesity is increasingly recognized as a chronic metabolic disease in China, with the adult overweight and obesity rate reaching 51.2%. If not effectively addressed, this rate is projected to rise to 70.5% by 2030 [3]. - The use of scientifically-based pharmacological interventions is essential for effective weight management, as evidenced by the clinical trials demonstrating significant weight loss and metabolic improvements with Masitide [3]. Product Details - Masitide's dual-target mechanism enhances weight loss effects compared to single-target GLP-1 drugs, leading to reductions in visceral fat and improvements in hypertension, hyperglycemia, hyperlipidemia, and hyperuricemia [3]. - Clinical trials showed that doses of 4mg and 6mg of Masitide over 32 and 48 weeks resulted in significant weight loss and reductions in waist circumference, blood pressure, blood lipids, blood uric acid, and transaminases [3]. Market Launch and Accessibility - The drug is available for patients through JD Health's platform, allowing them to search for "Xinermai" and connect with local medical institutions for appointments [1][4]. - The innovative injection device for Masitide offers enhanced convenience and safety, featuring a needle-free design and painless injection technology [4]. Strategic Collaboration - JD Health's collaboration with Innovent Biologics aims to leverage its multi-channel advantages and healthcare service capabilities to provide patients with more accessible and scientific weight management solutions [5]. - The launch of Xinermai represents a new treatment option for overweight and obese patients in China, with potential applications expanding into areas like fatty liver and adolescent obesity [5].

Core Viewpoint - The article emphasizes the importance of weight management as a national strategy in China, particularly in the context of chronic disease prevention and control, highlighting the launch of a three-year "Weight Management Year" initiative starting in 2024 [3][9]. Group 1: National Strategy and Policy - In 2024, weight management will be elevated to a national strategic level, with a three-year initiative launched by the National Health Commission in collaboration with 16 other departments [3]. - By April 2025, the "Healthy Weight Management Action" will be officially included in the "Healthy China 2030 Action" overall plan, showcasing a comprehensive policy framework at national, provincial, and municipal levels [3][11]. Group 2: Chronic Disease Burden - Chronic diseases account for over 70% of the total disease burden in China, with abnormal weight being a significant health risk [7]. - The overweight rate among adults has reached 50.7%, with central obesity affecting over 280 million people, and the hidden obesity rate (normal BMI but high body fat) at 30% [7]. - Overweight and obesity are linked to a 40%-200% increased risk of 13 types of cancer, and the obesity rate among adolescents has increased 11 times over the past 20 years [7]. Group 3: Community and Individual Responsibility - The initiative calls for a collaborative effort among government, industry, organizations, and individuals to create a supportive environment for weight management [10]. - The government aims to curb the rising obesity rate and increase public health literacy from 18% in 2024 to 30% by 2030 [11]. Group 4: Market Opportunities - By 2025, the health weight management industry is expected to experience explosive growth, creating a new health consumption market worth over 380 billion yuan, driven by policy support, technological advancements, and consumer upgrades [12]. - Notable weight loss brands are emerging, gaining popularity among health-conscious consumers [12]. Group 5: Family and Personal Actions - Families are encouraged to adopt tools for weight management and emphasize the importance of monitoring children's health [13]. - Individuals are urged to understand the risks of overweight and obesity and to manage their weight through informed dietary, exercise, and lifestyle choices [14].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 自去年起，减重诊疗对公立医院来说，已经从"可选项"变成了必须认真布局的新任务。 2024年6月，国家卫生健康委联合16个部门发布了《"体重管理年"活动实施方案》，明确鼓励有条件的医疗卫生机构设立体重管理门诊。政策 要求，国家卫生健康委、国家中医药局直属及管理医院，以及各省（区、市）属综合医院、儿童医院、中医医院，要在2025年6月底前基本实 现体重管理门诊的全覆盖。 随着政策"最后期限"临近，各地医院纷纷加快步伐，地方卫健委也陆续公布本地体重管理门诊的建设进展。 据公开报道，北京已有119家二级及以上医院和76家基层卫生服务中心可提供体重管理服务；广州有63家医院开设了体重管理门诊；浙江全省 249家二级及以上医疗机构已设立体重管理门诊，累计服务患者超过20万人次；四川则有446家医疗机构开设了体重管理或肥胖防治门诊。 目前，外科、内分泌、营养、中医等多个科室纷纷进军减重领域，院内形成了激烈的"赛马"态势，有的医院甚至设立了七八个减重门诊，科室 之间竞 ...

Core Viewpoint - The STEP 5 trial demonstrates that semaglutide 2.4 mg is effective for long-term weight management in obese adults without type 2 diabetes, showing significant and sustained weight loss over a two-year period [2][3][4]. Group 1: Trial Overview - STEP 5 is a phase 3b randomized, double-blind, placebo-controlled trial involving 304 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) [3][4]. - Participants were assigned to receive either weekly subcutaneous injections of 2.4 mg semaglutide or a placebo, alongside a low-calorie diet and increased physical activity, for 104 weeks [3][4]. - The primary endpoint was the percentage change in weight and the proportion of participants achieving a weight loss of ≥5% by week 104 [3]. Group 2: Weight Loss Results - The semaglutide group experienced a weight loss of -15.2%, compared to -2.6% in the placebo group [4]. - 77.1% of participants in the semaglutide group lost at least 5% of their body weight, while only 34.4% in the placebo group achieved this [4]. Group 3: Safety and Side Effects - Common adverse events associated with semaglutide included nausea, diarrhea, vomiting, constipation, and abdominal pain [6]. - The safety profile of semaglutide in STEP 5 was consistent with previous trials, with 5.9% of patients discontinuing treatment due to adverse events [6]. Group 4: Health Improvements - Significant improvements were observed in waist circumference (-14.4 cm in the semaglutide group vs. -5.2 cm in the placebo group) and systolic blood pressure (-5.7 mmHg vs. -1.6 mmHg) [7]. - Semaglutide also improved various metabolic health markers, including HbA1c, fasting blood glucose, and lipid profiles [7]. Group 5: STEP Trial Context - The STEP program is a comprehensive phase 3 clinical development plan for semaglutide, involving approximately 4,500 overweight or obese adults across multiple trials [8].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 ▍2025年最新标准体重对照表 很多人总为体重数字焦虑，尤其女性常认为"体重过百"就是肥胖，非得减至100斤以下才算瘦，却忽视了身高差异和整体健康状况。 让我们参考2025年最新标准体重对照表，你或许会发现——自己其实并不胖！ 若一位175cm的男性体重145斤，实际属于标准范围，完全不算肥胖。特别值得注意的是，这类标准表格并不适用于健身人群，因为他们体重普 遍较高但身材紧实。例如同样175cm的健身男性，即使体重达160斤，身材依然可能相当匀称而非肥胖。 对于163cm的女性而言，体重115斤其实仅是标准水平，而非超标。不应为追求"两位数体重"而牺牲健康。同理，这一标准也不适用于健身女 性，她们因肌肉含量高而体重偏大，但身材却往往更加紧致有型。 因此，判断身材是否肥胖，BMI值比单纯体重更具参考价值。 BMI计算公式为：体重(kg)÷身高(m)²。BMI超过24为超重，超过28则属肥胖。对照自身BMI值所在范围即可判断体型状况，不必盲目减重。体 重绝 ...